Glycobiology and protein degradation
GlycoEra AG
Incorporated
08.12.2020Headquarters
WädenswilSupport
GlycoEra AG is a biotechnology company building a high-value pipeline of medicines in precision immunology based on deep expertise in glycobiology and protein degradation. GlycoEras innovative CustomGlycan platform enables the design, engineering, and development of novel biologics for a broad range of indications. GlycoEra is advancing a range of assets toward human clinical studies.
News
ZKB Pionierpreis Technopark presents shortlist (startupticker.ch)
Executive hires to help startups scale (startupticker.ch)
GlycoEra raises USD 130 Million Series B to advance targeted autoimmune therapies (venturelab.swiss)
GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases (startupticker.ch)
Bristol Myers Squibb invests in GlycoEra (startupticker.ch)
Startups welcome seasoned industry leaders to their board (startupticker.ch)
Startups rely on seasoned board members’ expertise (startupticker.ch)
C-Level managers for tech startups (startupticker.ch)
GlycoEra seals series A financing round at CHF 45 million (startupticker.ch)
LimmaTech launches spin-out for drug development (startupticker.ch)
